Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorIranzo Gómez, Patricia
dc.contributor.authorPardo Aranda, Nuria
dc.contributor.authorCallejo Perez, Ana
dc.contributor.authorCedres Perez, Susana
dc.contributor.authorMartínez Marti, Alexandre
dc.contributor.authorNavarro Mendivil, Alejandro
dc.contributor.authorSoleda, Mireia
dc.contributor.authorJiménez Flores, José Antonio
dc.contributor.authorHernandez Losa, Javier
dc.contributor.authorVivancos Prellezo, Ana
dc.contributor.authorFelip Font, Enriqueta
dc.contributor.authorAmat, Ramon
dc.contributor.authorCarbonell, Caterina
dc.contributor.authorFrigola Rissech, Joan
dc.date.accessioned2022-09-06T08:56:57Z
dc.date.available2022-09-06T08:56:57Z
dc.date.issued2022-04
dc.identifier.citationFrigola J, Carbonell C, Irazno P, Pardo N, Callejo A, Cedres S, et al. High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC. J Immunother Cancer. 2022 Apr;10(4):e004197.
dc.identifier.issn2051-1426
dc.identifier.urihttps://hdl.handle.net/11351/8030
dc.descriptionImmunoteràpia; Càncer de pulmó; Biomarcadors tumorals
dc.description.sponsorshipThis work was supported by Merck Healthcare KGaA, Darmstadt, Germany (Grant for Oncology Innovation to the Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain), Fundación Cientifica Asociación Española Contra el Cancer-AECC (grant number GCB14142170 to EF); the Catalan Government/AGAUR (2017–SGR–1738 to EF). Merck Healthcare KGaA reviewed the manuscript for medical accuracy only before journal submission.
dc.language.isoeng
dc.publisherBMJ
dc.relation.ispartofseriesJournal for ImmunoTherapy of Cancer;10(4)
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectAnomalies cromosòmiques
dc.subjectPulmons - Càncer - Tractament
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.mesh/drug therapy
dc.subject.meshChromosome Aberrations
dc.titleHigh levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1136/jitc-2021-004197
dc.subject.decscarcinoma de pulmón de células no pequeñas
dc.subject.decs/farmacoterapia
dc.subject.decsaberraciones cromosómicas
dc.relation.publishversionhttp://dx.doi.org/10.1136/jitc-2021-004197
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Frigola J, Carbonell C, Soleda M, Amat R] Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Irazno P, Pardo N, Callejo A, Cedres S, Martinez-Marti A, Navarro A] Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Jimenez J] Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Hernandez-Losa J] Servei de Patologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Vivancos A] Cancer Genomics Laboratory, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Felip E] Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid35477861
dc.identifier.wos000788620500001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple